Gsk (GSK) Interest & Investment Income (2009 - 2026)

Gsk's Interest & Investment Income history runs 18 years deep, the most recent figure standing at $77.8 million for Q2 2026.

• In Q2 2026, Interest & Investment Income rose 16.66% year-over-year to $77.8 million; the TTM figure through Jun 2026 stood at $280.9 million (up 13.19% YoY), while the FY2025 annual figure was $222.8 million, up 42.88% from the prior year.
• Interest & Investment Income for Q2 2026 stood at $77.8 million, up from $29.7 million in the prior quarter.
• The five-year high for Interest & Investment Income was $138.3 million in Q4 2025, with the low at $9.4 million in Q1 2022.
• The 5-year median for Interest & Investment Income is $37.9 million (2023), against an average of $48.8 million.
• The sharpest annual moves came in 2022 and 2026: Interest & Investment Income surged 373.01% in 2022, then plunged 56.39% in 2026.
• Gsk's Interest & Investment Income stood at $32.8 million in 2022, then jumped by 134.31% to $77.0 million in 2023, then retreated by 6.6% to $71.9 million in 2024, then soared by 92.47% to $138.3 million in 2025, then tumbled by 43.75% to $77.8 million in 2026.
• Business Quant data shows GSK's Interest & Investment Income at $77.8 million in Q2 2026, $29.7 million in Q1 2026, and $138.3 million in Q4 2025.